SVCM
Saturn V Capital Management Portfolio holdings
AUM
$552M
1-Year Est. Return
551.78%
This Fund
S&P 500
1 Year Est. Return
+551.78%
AUM
$552M
AUM Growth
+$7.32M
(+1.3%)
Holding
24
Top Buys
| 1 | +$15.8M | |
| 2 | +$10.5M | |
| 3 | +$5.9M | |
| 4 |
Immix Biopharma
IMMX
|
+$5.1M |
| 5 |
Zura Bio
ZURA
|
+$4.47M |
Top Sells
| 1 | +$21.8M | |
| 2 | +$18.3M | |
| 3 | +$14.9M | |
| 4 |
Dyne Therapeutics
DYN
|
+$14.2M |
| 5 |
ABVX
Abivax
ABVX
|
+$12.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALMS
1
Alumis Inc
ALMS
$2.55B
| $70.5M | 12.77% |
3,202,075
+66,122
|
|
||
2
Amylyx Pharmaceuticals
AMLX
$1.48B
| $60.5M | 10.95% |
4,349,885
-146,602
|
|
||
|
ABVX
3
Abivax
ABVX
$5.78B
| $60.4M | 10.94% |
542,696
-106,483
|
|
||
4
Vaxcyte
PCVX
$6.85B
| $47.9M | 8.68% |
824,532
+25,592
|
|
||
5
Pharvaris
PHVS
$2.03B
| $33.9M | 6.15% |
1,201,402
+61,369
|
|
||
|
6
Immix Biopharma
IMMX
$596M
| $33.6M | 6.09% |
3,693,585
+694,416
|
|
||
7
Celcuity
CELC
$4.46B
| $32.2M | 5.83% |
281,904
-35,191
|
|
||
8
Jazz Pharmaceuticals
JAZZ
$14.2B
| $30.8M | 5.58% |
162,961
-85,109
|
|
||
9
Disc Medicine
IRON
$2.6B
| $28.8M | 5.21% |
449,926
+151,497
|
|
||
10
X4 Pharmaceuticals
XFOR
$381M
| $26.7M | 4.83% |
6,456,646
+656,116
|
|
||
11
Cogent Biosciences
COGT
$5.6B
| $24.1M | 4.37% |
626,635
-590,429
|
|
||
12
Monopar Therapeutics
MNPR
$410M
| $18.9M | 3.43% |
345,626
+19,925
|
|
||
|
13
Dyne Therapeutics
DYN
$2.85B
| $17.5M | 3.17% |
966,609
-822,007
|
|
||
14
Invivyd
IVVD
$336M
| $14.2M | 2.58% |
10,949,084
+3,213,698
|
|
||
15
Candel Therapeutics
CADL
$617M
| $14.2M | 2.57% |
+2,896,588
|
|
||
16
Oculis Holding
OCS
$742M
| $13.7M | 2.49% |
516,761
|
|
||
17
Ovid Therapeutics
OVID
$448M
| $9.25M | 1.68% |
4,166,666
+1,666,666
|
|
||
18
Inhibikase Therapeutics
IKT
$224M
| $6.49M | 1.18% |
3,863,445
+6,646
|
|
||
|
19
Zura Bio
ZURA
$389M
| $4.4M | 0.8% |
+739,960
|
|
||
20
Alto Neuroscience
ANRO
$657M
| $2M | 0.36% |
+88,999
|
|
||
|
MSLE
21
Satellos Bioscience
MSLE
$145M
| $1.97M | 0.36% |
+350,000
|
|
||
|
IVA
22
Inventiva
IVA
$855M
| – | – |
-283,166
|
|
||
23
Ocular Therapeutix
OCUL
$1.82B
| – | – |
-1,504,880
|
|
||
|
CNTA
24
Centessa Pharmaceuticals
CNTA
$6.17B
| – | – |
-282,692
|
|